HOME >> MEDICINE >> NEWS
Italian researchers find fenretinide cuts the risk of second breast cancers in young women

A 15-year follow-up of women in a breast cancer trial has found that fenretinide[1] a drug related to vitamin A significantly cuts the risk of a second breast cancer among younger patients.

The Italian research team reporting the findings on-line (Thursday 4 May) in Annals of Oncology[2], are sufficiently convinced of the drug's protective potential to call for a trial to test its use as a preventive in pre-menopausal healthy women at high risk of the disease. They are now seeking international partners and funding for such a trial.

The women in the long-term follow-up comprised a sub-group of 1,700 60% of the patients in a 10-centre trial lead by Professor Umberto Veronesi and co-ordinated by Milan's Istituto Nazionale Tumori when he was its director. The study, which began in 1987, randomised more than 2,800 women to receive 200 mg fenretinide daily for five years or no extra treatment after surgery for early-stage breast cancer.

The new analysis, also lead by Professor Veronesi, who is now Director of the European Institute of Oncology in Milan, followed the 1,739 patients who had been recruited by the Istituto Nazionale Tumori centre, investigating whether these patients developed a second cancer either in the treated breast or the other breast.

Co-author Dr Andrea Decensi, Director of the Department of Medical Oncology at the Galliera Hospital in Genoa, said: "We followed these patients for between 12 and 16 years and we found 168 second breast cancers in the fenretinide arm and 190 in the control arm. In post-menopausal women there were actually more cancers in the fenretinide arm than among the controls (85 as against 64). But, among pre-menopausal women there were only 83 second cancers in the fenretinide group compared with 126 in the control group.

Dr Decensi said that overall, this meant a 17% reduction in second cancers among the fenretinide group, which was of borderline statistical significance. But, there we
'"/>

Contact: Margaret Willson
m.willson@mwcommunications.org.uk
44-015-367-72181
European Society for Medical Oncology
3-May-2006


Page: 1 2 3

Related medicine news :

1. UCLA, Italian chemists move closer to solving Lou Gehrigs disease mystery
2. Italian doctors get their information on medicines from drug company sales reps
3. Italian public smoking ban leads to fall in hospital heart attack admissions in under 60s
4. UPMC joins Italian government to create $398 million biomedical research center in Sicily
5. Italian law on ART brings problems for doctors and patients
6. Stanford researchers find culprit in aging muscles that heal poorly
7. UCLA researchers awarded $9M contract for study identifiying antibiotic treatment for MRSA
8. Penn researchers discover novel pathway for increasing good cholesterol
9. Theory of facial aging gets a facelift from UT Southwestern researchers
10. UIC researchers to develop new drugs to fight bioterrorism
11. UQ researchers discover some of the oldest forms of life

Post Your Comments:
(Date:7/29/2014)... Premier Women’s Health , a six-physician ... has affiliated with Allegheny Health Network’s renowned Women’s Health ... babies and perform surgical procedures at Heritage Valley Sewickley. ... referred to Allegheny Health Network’s West Penn Hospital ... West Penn Hospital and its highly regarded Women’s Health ...
(Date:7/29/2014)... Boca Raton, FL (PRWEB) July 29, 2014 ... will officially launch its products in the UK in September. ... company’s products will be available Sept. 7 on Amazon.co.uk. , ... has been growing and we are truly looking forward to ... Amazon.co.uk will include OZ Naturals bestselling Vitamin C serum ...
(Date:7/29/2014)... 29, 2014 Representatives with BNatrl announced ... called BNatrl Silver Solution 12ppm . , “It’s ... spokesperson for BNatrl LLC. “It helps boost your immune ... harmful pathogens and microbes.” , BNatrl develops and manufactures ... products, with 10 percent of profits being used to ...
(Date:7/29/2014)... IsoComforter, Inc ., one of the ... the introduction of the innovative new Iso-Hip Wrap. ... for post operative hip replacement patients. The plush design ... benefits of cold therapy while resting, sitting, or standing. ... are done every year. Cold therapy is the ...
(Date:7/29/2014)... July 29, 2014 Regents Health Resources, ... services, has brought health care industry veteran Daryl Demonbreun ... to help lead the company’s ambitious plans to grow ... Health has been moving along at a steady pace ... it up a notch,” says Bob Maier, founder and ...
Breaking Medicine News(10 mins):Health News:Leading West Suburban OBGYN Practice, Premier Women’s Health, Joins Allegheny Health Network 2Health News:Leading West Suburban OBGYN Practice, Premier Women’s Health, Joins Allegheny Health Network 3Health News:OZ Naturals to Launch Its Products in the UK 2Health News:BNatrl Launches New Silver Solution Product 2Health News:New IsoComforter Cold Therapy Unit Plus Hip Wrap Gives Post Operative Hip Replacement Patients Faster Recovery Times 2Health News:Sferrella and Demonbruen Join Regents Health Resources 2
(Date:7/29/2014)... , July 29, 2014 ... Market Research "Orthopedic Trauma Fixation Devices Market - Global ... - 2020", the global orthopedic trauma fixation devices market ... is expected to grow at a CAGR of 7.2% ... of USD 9.3 billion in 2020. Browse ...
(Date:7/29/2014)... -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced ... 2014 financial results after the Nasdaq market closes on ... live conference call and webcast to discuss its financial ... 7, 2014 at 8:00 a.m. Eastern Time (5:00 a.m. ... conference call by dialing 866-952-1907 (US) or 785-424-1826 (International) ...
(Date:7/29/2014)... July 29, 2014  Instrumentation Laboratory (IL) today announced the ... corporate logo. This is part of a comprehensive rebranding effort ... in Boston, MA , in 1959, IL ... since 1992.  Other companies in the group include Inova Diagnostics ... ( Barcelona, Spain ).  Like IL, these three ...
Breaking Medicine Technology:Orthopedic Trauma Fixation Devices Market is Expected to Reach USD 9.3 Billion Globally in 2020: Transparency Market Research 2Orthopedic Trauma Fixation Devices Market is Expected to Reach USD 9.3 Billion Globally in 2020: Transparency Market Research 3Orthopedic Trauma Fixation Devices Market is Expected to Reach USD 9.3 Billion Globally in 2020: Transparency Market Research 4Neurocrine Biosciences Announces Conference Call And Webcast To Report Second Quarter 2014 Financial Results 2Instrumentation Laboratory Unveils New Corporate Brand 2Instrumentation Laboratory Unveils New Corporate Brand 3
Cached News: